Imugene Limited (IUGNF)
OTCMKTS · Delayed Price · Currency is USD
0.2000
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST
Imugene Market Cap
Imugene has a market cap or net worth of $59.29 million as of February 12, 2026. Its market cap has decreased by -67.26% in one year.
Market Cap
59.29M
Enterprise Value
51.29M
Revenue
2.88M
Ranking
n/a
PE Ratio
n/a
Stock Price
$0.20
Market Cap Chart
Since September 17, 2002, Imugene's market cap has increased from 4.04M to 59.29M, an increase of 1,368.01%. That is a compound annual growth rate of 12.15%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 12, 2026 | 59.29M | -23.20% |
| Dec 31, 2025 | 77.21M | -54.66% |
| Dec 31, 2024 | 170.29M | -68.32% |
| Dec 29, 2023 | 537.56M | -15.06% |
| Dec 30, 2022 | 632.87M | -62.26% |
| Dec 31, 2021 | 1.68B | 358.47% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| HST Global | 139.70M |
| Vaxart | 137.92M |
| BioStem Technologies | 92.40M |
| Nuo Therapeutics | 72.43M |
| VitaSpring Biomedical | 51.78M |
| Vicapsys Life Sciences | 48.56M |
| Arch Biopartners | 43.92M |
| Cell Source | 41.50M |